Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

73.1K
Overview
73.1K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

2.0K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.0K
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

329
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
329

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Clinical Respiratory Score: Diagnostic Performance for Acute Chest Syndrome in Sickle Cell Disease.

Pediatric pulmonology·2026
Same author

Cancer-associated arterial thromboembolism: real-world burden from a nationwide electronic health record database.

Journal of the National Cancer Institute·2026
Same author

Lung Transplantation for Pulmonary Alveolar Proteinosis - a Retrospective International Multi-Center Analysis.

The European respiratory journal·2026
Same author

Concomitant bilateral lung transplantation and diaphragmatic hernia repair: A case report.

JTCVS techniques·2026
Same author

Evaluating the role of high-dose intravenous thiamine supplementation for lactate clearance in patients with cirrhosis and sepsis.

International journal of critical illness and injury science·2026
Same author

Deciphering the single-cell molecular landscape of ampullary cancer: A rare gastrointestinal malignancy.

iScience·2026

Related Experiment Video

Updated: Sep 14, 2025

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation
11:49

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation

Published on: May 2, 2013

16.2K

Antithymocyte globulin therapy in chronic lung allograft dysfunction.

Akhilesh Ajay Padhye1, Danielle Guffey2, Andres Leon-Pena1

  • 1Section of Pulmonary and Critical Care Medicine, Baylor College of Medicine, Houston, TX, United States.

Frontiers in Transplantation
|July 21, 2025
PubMed
Summary

Anti-thymocyte globulin (ATG) did not improve lung function in lung transplant recipients with chronic lung allograft dysfunction (CLAD). However, ATG was associated with improved survival, warranting further investigation in randomized trials.

Keywords:
ATGCLADFEV1anti-thymocyte globulinchronic lung allograft dysfunctionlung function

More Related Videos

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

14.7K
In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

14.5K

Related Experiment Videos

Last Updated: Sep 14, 2025

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation
11:49

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation

Published on: May 2, 2013

16.2K
Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

14.7K
In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

14.5K

Area of Science:

  • Immunology
  • Transplantation Medicine
  • Pulmonology

Background:

  • Lung transplantation survival has improved, but long-term outcomes are limited by chronic lung allograft dysfunction (CLAD).
  • CLAD is a primary driver of graft failure and mortality after the first year post-transplant.
  • Anti-thymocyte globulin (ATG) is a treatment for refractory CLAD, but its effectiveness is not well-established.

Purpose of the Study:

  • To retrospectively evaluate the effect of ATG on lung function decline in lung transplant recipients with CLAD.
  • To assess the impact of ATG on mortality among patients diagnosed with CLAD.

Main Methods:

  • Retrospective analysis of 124 lung transplant recipients diagnosed with CLAD (defined as >20% FEV1 decline).
  • Comparison of FEV1 decline rates between patients treated with ATG and those not receiving ATG using mixed-effects modeling.
  • Analysis of all-cause mortality using Fine-Gray competing risk modeling.

Main Results:

  • Of 124 CLAD patients, 55 (44%) received ATG.
  • ATG treatment did not significantly alter FEV1 decline rates compared to pre-ATG rates or non-ATG recipients.
  • ATG administration was associated with a reduced hazard of all-cause mortality (subhazard ratio 0.66).

Conclusions:

  • ATG treatment did not demonstrate a significant benefit in preserving lung function in CLAD patients.
  • ATG was associated with improved survival in this cohort.
  • Further prospective, randomized studies are necessary to confirm these findings and establish ATG's role in CLAD management.